BeStock  
Stocks › Biotechnology › ASND

Ascendis Pharma A/S ASND

US equityMarket cap rank #1027Biotechnology
$252.73 −$3.23 (-1.26%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $252.73 0.00%
Open$255.44
Prev close$255.96
Day range$251.55 – $256.65
Volume602.9K
Market cap$16.63B
P/E (TTM)34.7
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026 · reported in EUR

Revenue€369.66M+73.0% YoY
Operating profit€124.58M+1,032.8% YoY
Net profit€73.97M+221.3% YoY
Diluted EPS€1.08+208.0% YoY
Free cash flow€186.03M+8,758.6% YoY
Operating cash flow€188.79M

Revenue, last 8 quarters

€173.9MDec '24€101.0MMar '25€158.0MJun '25€213.6MSep '25€247.5MDec '25€246.6MMar '26€339.3MJun '26€369.7MSep '26

Net profit, last 8 quarters

€-38.5MDec '24€-94.6MMar '25€-38.9MJun '25€-61.0MSep '25€-33.6MDec '25€629.3MMar '26€207.0MJun '26€74.0MSep '26

Diluted EPS by quarter

-0.64Dec '24-1.58Mar '25-0.82Jun '25-1.00Sep '25-0.55Dec '259.75Mar '262.83Jun '261.08Sep '26

Free cash flow by quarter

€-87.6MDec '24€-14.3MMar '25€-12.4MJun '25€2.1MSep '25€70.0MDec '25€-7.7MMar '26€270.7MJun '26€186.0MSep '26

Annual revenue

€7.0MFY20€7.8MFY21€51.2MFY22€266.7MFY23€363.6MFY24€720.1MFY25

Profitability & balance sheet

Gross margin91.9%
Operating margin31.3%
Net margin72.9%
Return on equity132.2%
Return on assets49.0%
Return on invested capital69.9%
Current ratio2.89
Liabilities / assets38.2%
Cash & investments€964.36M
Total debt€447.81M
Net cash (debt)€516.56M
Free cash flow / sales43.1%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • YORVIPATH€290.63M 78.6%
  • SKYTROFA€59.42M 16.1%
  • YUVIWEL€15.64M 4.2%
  • Licenses, services and clinical supply€3.97M 1.1%

This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.

Income statement

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Total Revenue as Reported €369.66M €339.29M €246.60M €720.13M €247.50M
Total Operating Revenue €369.66M €339.29M €246.60M €720.13M €247.50M
Cost of Revenue €28.31M €27.66M €17.52M €94.92M €23.60M
Gross Profit €341.35M €311.63M €229.09M €625.22M €223.90M
Operating Expense €216.77M €91.16M €204.27M €761.49M €217.46M
Selling and Admin Expenses €145.14M €171.68M €145.23M €448.04M €135.00M
-General & Admin Expense €145.14M €171.68M – €448.04M €135.00M
Research & Development €69.93M €75.89M €59.04M €303.62M €78.15M
Depreciation & Amortization & Depletion €1.71M €1.66M – €9.82M €4.31M
-Depreciation & Amortization €1.71M €1.66M – €9.82M €4.31M
Operating Profit €124.58M €220.47M €24.81M -€136.27M €6.44M
Net Non-Operating Interest Income (Expense) -€4.39M -€1.03M -€62.74M -€44.88M €4.30M
Non-Operating Interest Income €7.65M €4.83M €4.52M €15.30M €4.37M
Non-Operating Interest Expense €12.04M €14.17M €67.26M €80.65M €20.54M
Other Income (Expense) -€6.81M €10.66M -€10.25M -€31.50M -€37.45M
Gain on Sale of Security €55,000.00 €6.82M – -€47.81M -€42.23M
Earnings from Equity Interest -€6.87M €3.84M -€10.25M €16.31M €1.33M
Special Income (Charges) €0.00 €0.00 – – –
-Less:Impairment of Capital Assets €0.00 €0.00 – – –
Pretax Profit €113.37M €230.09M -€48.18M -€212.65M -€26.71M
Tax €39.40M €23.12M -€677.52M €15.38M €6.86M
Net Profit €73.97M €206.97M €629.34M -€228.03M -€33.56M
Profit from Continuing Operations €73.97M €206.97M €629.34M -€228.03M -€33.56M
Net Income to Parent Company €73.97M €206.97M €629.34M -€228.03M -€33.56M
Net Income to Common Stockholders €73.97M €206.97M €629.34M -€228.03M -€33.56M
Basic EPS €1.13 €3.22 €10.20 -€3.76 -€0.55
Diluted EPS €1.08 €2.83 €9.75 -€3.76 -€0.55
Other Operating Expenses – -€158.07M – – –
Total Other Finance Costs – -€8.31M – -€20.47M –

Balance sheet

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Total Assets €2.43B €2.29B €2.00B €1.30B €1.30B
Total Current Assets €1.59B €1.39B €1.12B €1.11B €1.11B
Cash and Cash Equivalents & Short-Term Investments €964.36M €812.26M €572.82M €616.04M €616.04M
-Cash and Cash Equivalents €964.36M €812.26M €572.82M €616.04M €616.04M
Receivables €254.42M €224.10M €196.61M €157.70M €157.70M
-Accounts Receivable €225.84M €206.51M €178.68M €141.33M €141.33M
-Taxes Receivable €11.89M €1.99M €1.26M €1.78M €1.78M
-Other Receivables €16.68M €15.60M €16.67M €14.58M €14.58M
Prepaid Assets €36.83M €43.47M €38.57M €33.72M €33.72M
Inventory €331.35M €310.58M €314.34M €301.53M €301.53M
Total Non-Current Assets €840.23M €895.61M €880.94M €193.59M €193.59M
Net PPE €134.94M €135.69M €135.92M €146.48M €146.48M
Investments and Advances €24.11M €30.48M €23.56M €32.53M €32.53M
-Long Term Equity Investment €24.11M €30.48M €23.56M €32.53M €32.53M
Non Current Accounts Receivables €25.64M €26.49M €27.37M €10.87M €10.87M
Goodwill and Other Intangible Assets €3.66M €3.68M €3.69M €3.71M €3.71M
Non-Current Deferred Assets €651.89M €699.28M €690.41M – –
Total Liabilities €926.73M €849.53M €1.52B €1.47B €1.47B
Total Current Liabilities €549.08M €464.89M €1.13B €1.07B €1.07B
Payables €122.35M €116.58M €86.39M €97.08M €97.08M
-Accounts Payable €109.72M €103.92M €78.59M €90.66M €90.66M
-Total Tax Payable €12.64M €12.66M €7.81M €6.43M €6.43M
Short-Term Debt and Capital Lease Obligation €70.15M €65.43M €510.56M €486.53M €486.53M
-Current Debt €70.15M €65.43M €510.56M €486.53M €486.53M
Current Provisions €265.17M €221.41M €176.65M €166.40M €166.40M
Current Deferred Liabilities €3.89M €2.78M €5.36M €4.94M €4.94M
Other Current Liabilities €87.52M €58.69M €347.80M €314.44M €314.44M
Total Non-Current Liabilities €377.65M €384.64M €388.54M €396.00M €396.00M
Long Term Debt and Capital Lease Obligation €377.65M €384.64M €386.11M €385.25M €385.25M
-Long Term Debt €377.65M €384.64M €386.11M €385.25M €385.25M
Non-Current Deferred Liabilities €0.00 €0.00 €2.44M €10.75M €10.75M
Total Equity €1.50B €1.44B €487.97M -€162.82M -€162.82M
Stockholders' Equity €1.50B €1.44B €487.97M -€162.82M -€162.82M
Capital Stock €8.91M €8.89M €8.38M €8.32M €8.32M
-Common Stock €8.91M €8.89M €8.38M €8.32M €8.32M
Other Equity Interests €1.49B – €479.59M -€171.14M -€171.14M
Additional Paid-In Capital – €3.30B – – –
Retained Earnings – -€1.88B – – –
Less: Treasury Stock – -€69,000.00 – – –
Gains/Losses Not Affecting Retained Earnings – €6.16M – – –
-Gross PPE – – – €222.90M €222.90M
-Accumulated Depreciation – – – -€76.42M -€76.42M
-Goodwill – – – €3.50M €3.50M
-Other Intangible Assets – – – €215,000.00 €215,000.00

Cash flow

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Operating Cash Flow €188.79M €281.68M -€7.72M €53.90M €73.40M
Net cash flow from continuing operations €188.79M €281.68M -€7.72M €53.90M €73.40M
Net Income from Continuing Operations €73.97M €206.97M €629.34M -€228.03M -€33.56M
Gain/Loss from Continuing Operations €6.87M -€3.82M €10.25M -€16.31M -€1.33M
Depreciation & Depletion & Amortization €4.64M €4.57M €4.22M €17.70M €4.82M
Deferred Tax €39.40M €23.12M -€677.52M €15.38M €6.86M
Other Non-Cash Items €3.87M -€8.27M €62.10M €87.06M €35.30M
Change in Working Capital €89.87M -€7.39M -€66.82M €70.96M €39.86M
-Change in Receivables -€18.31M -€24.67M -€36.38M €15.59M -€9.55M
-Change in Inventory -€20.78M €3.77M -€12.81M -€5.92M €501,000.00
-Change in Prepaid Assets €6.65M -€4.64M -€4.85M -€6.05M -€4.32M
-Change in Payables and Accrued Expense €27.75M €29.71M -€21.05M -€10.37M €22.72M
-Change In Other Working Capital €94.56M -€11.56M €8.27M €77.72M €30.51M
Net cash flow from investing -€2.10M -€2.85M -€6.75M -€8.49M -€3.39M
Net Cash Flow from Continuing Investing Activities -€2.10M -€2.85M -€6.75M -€8.49M -€3.39M
Net PPE Purchase and Sale -€2.76M -€11.91M €959,000.00 -€8.49M -€3.39M
Net Other Investing Changes €662,000.00 €9.05M -€7.71M – –
Financing Cash Flow -€38.47M -€46.12M -€36.83M €36.33M €8.52M
Net Cash Flow from Continuing Financing Activities -€38.47M -€46.12M -€36.83M €36.33M €8.52M
Net Issuance Payments Of Debt -€9.03M -€8.14M -€8.58M -€21.96M -€6.83M
Net Common Stock Issuance -€52.43M -€51.56M -€51.86M -€17.40M €0.00
Proceeds from Stock Option Exercised €22.98M €18.46M €31.63M €87.08M €15.35M
Net Other Financing Charges €0.00 -€4.89M -€8.02M -€11.40M €0.00
Ending Cash Balance €964.36M €812.26M €572.82M €616.04M €616.04M
Net Change in Cash €148.22M €232.71M -€51.31M €81.74M €78.52M
Beginning Cash Balance €812.26M €572.82M €616.04M €559.54M €539.09M
Effect of Exchange Rate Changes €3.89M €6.73M €8.09M -€25.24M -€1.58M
Free Cash Flow €186.03M €270.73M -€7.72M €45.41M €70.01M
Net Investment Purchase and Sale – – – €0.00 €0.00

Discussion

No comments yet — be the first to weigh in on ASND.

Sign in to join the discussion.

Scroll to Top